Development of the Guideline for HIV Testing in South Korea with Low Prevalence of HIV-1 Infection Based on the Expert Consensus

Hee Jung Choi, Kyoung Ae Kong, Jung Won Min, Hun-Jae Lee, Hae-Sook Park

.

DOI: 10.4236/wja.2011.14023                

Abstract

Purpose: This study was conducted to develop a guideline for HIV testing in South Korea where the HIV prevalence is very low. It is necessary to make the recommendations presented here based on the epidemiology of opportunistic infection and cancer in the community. Methods: The development of a guideline for HIV testing was conducted using literature reviews and the agreement of Korean experts for HIV patients using a two-round Delphi consensus technique. Each expert was asked to independently answer to each item related to HIV risk. Ten experts participated in the two-round survey. Results: The individual items were determined based on the following categories: high risk behavior, symptom and diseases, colo-rectal diseases, uro-genital diseases and gynecology, skin and oral diseases. The final guideline consisted of 4-scale agreement rating (strongly recommended, recommended, not routinely recommended, no recommendation for routine provision). Discussion: We have developed the guideline for HIV testing in a country where the HIV prevalence is low based on a systematic investigation and expert consensus.

Keywords

HIV, Testing, Guideline, Consensus, Delphi Studies

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	UNAIDS, “AIDS Epidemic Update,” 2009. http://www.unaids.org
[2]	Korean CDC, “Development of Strategies for Activation in HIV Diagnostic Test in Korean Healthcare Settings,” 2006.
[3]	A. Jeong, H. W. Yim, S. H. Bae and W. C. Lee, “Changes of Hepatitis B Surface Antigen Seroprevalence in Korea, 1998-2005,” Korean Journal of Epidemiology, Vol. 30, No. 1, 2008, pp. 119-127. doi:10.4178/kje.2008.30.1.119
[4]	H. J. Kim, “Current Situation of Tuberculosis and Its Control in Korea,” Journal of the Korean Medical Association, Vol. 49, No. 9, 2006, pp. 762-772. doi:10.5124/jkma.2006.49.9.762
[5]	Centers for Disease Control and Prevention, “Revised Guidelines for HIV Counseling, Testing, and Referral,” MMWR Recommendations and Reports, Vol. 50, 2001, pp. 1-57.
[6]	B. M. Branson, H. H. Handsfield, M. A. Lampe, R. S. Janssen, A. W. Taylor, S. B. Lyss, et al., “Revised Recommendations for HIV Testing of Adults, Adolescents, and Pregnant Women in Health-Care Settings,” MMWR Recommendations and Reports, Vol. 55, 2006, pp. 1-17.
[7]	Korean CDC, “Revised Guidelines for HIV Counseling, Testing, and Referral,” 1999.
[8]	British HIV Association, British Association of Sexual Health and HIV, British Infection Society, “UK National Guidelines for HIV Testing,” 2008. http://www.bhiva.org/documents/Guidelines/Testing/GlinesHIVTest08.pdf
[9]	M. Poljak, E. Smit and J. Ross, “2008 European Guideline on HIV Testing,” International Journal of STD & AIDS, Vol. 20, No. 2, 2009, pp. 77-83. doi:10.1258/ijsa.2008.008438
[10]	World Health Organization and UNAIDS, “Guidance on Provider-Initiated Testing and Counseling in Health Facilities,” 2007. http://www.whqlibdoc.who.int/publications/2007/9789241595568_eng.pdf
[11]	H. A. Linstone, M. Turoff and O. Helmer, “The Delphi Method: Techniques and Applications,” 2002. http://is.njit.edu/pubs/delphibook/delphibook.pdf
[12]	Centers for Disease Control and Prevention, “Recommendations for Identification and Public Health Management of Persons with Chronic Hepatitis B Virus Infection,” MMWR Recommendations and Reports, Vol. 57, No. RR-8, 2008, pp. 1-20.
[13]	Centers for Disease Control and Prevention, “Revised Recommendations for HIV Screening of Pregnant Women,” MMWR Recommendations and Reports, Vol. 50, No. RR-19, 2001, pp. 63-85.
[14]	E. R. Cooper, M. Charurat, L. Mofenson, I. C. Hanson, J. Pitt and C. Diaz, “Combination Antiretroviral Strategies for the Treatment of Pregnant HIV-1—Infected Women and Prevention of Perinatal HIV-1 Transmission,” Journal of Acquired Immune Deficiency Syndromes, Vol. 29, No. 5, 2002, pp. 484-494.
[15]	L. M. Mofenson, “U.S. Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States,” MMWR Recommendations and Reports, Vol. 51, No, RR-18, 2002, pp. 1-38.
[16]	Centers for Disease Control and Prevention, “1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS among Adolescents and Adults,” MMWR Recommendations and Reports, Vol. 41, No. RR-7, 1992, pp. 1-19.
[17]	Centers for Disease Control and Prevention, “Trends in Tuberculosis—United States, 2008,” MMWR Recommendations and Reports, Vol. 58, No. 10, 2009, pp. 249- 253.
[18]	R. C. Burke, K. A. Sepkowitz, K. T. Bernstein, A. M. Karpati, J. E. Myers, B. W. Tsoi, et al. “Why Don’t Physicians Test for HIV? A Review of the United States Literature,” AIDS, Vol. 21, No. 12, 2007, pp. 1617-1624. doi:10.1097/QAD.0b013e32823f91ff
[19]	C. L. Jain, C. M. Wyatt, R. Burke, K. Sepkowitz and E. M. Begier, “Knowledge of the Centers for Disease Control and Prevention’s 2006 Routine HIV Testing Recommendations among New York City Internal Medicine Residents,” AIDS Patient Care and STDs, Vol. 23, No. 3, 2009, pp. 167-176. doi:10.1089/apc.2008.0130
[20]	S. M. Asch, A. S. London, P. F. Barnes and L. Gelberg, “Testing for Human Immunodeficiency Virus Infection among Tuberculosis Patients in Los Angeles,” American Journal of Respiratory and Critical Care Medicine, Vol. 155, No. 1, 1997, pp. 378-381.
[21]	S. Y. Low and P. Eng, “Human Immunodeficiency Virus Testing in Patients with Newly-Diagnosed Tuberculosis in Singapore,” Singapore Medical Journal, Vol. 50, 2009, pp. 479-481.